title: Pulmonary tuberculosis in HIV-infected patients in Zaire. A controlled trial of treatment for either 6 or 12 months.
abstract: BACKGROUND
  We studied the efficacy of a short-course regimen of chemotherapy for pulmonary tuberculosis in Kinshasa, Zaire. We also assessed whether, among patients with human immunodeficiency virus (HIV) infection, treatment should be extended from 6 to 12 months.
  
  
  METHODS
  HIV-seropositive and HIV-seronegative outpatients with pulmonary tuberculosis were treated with rifampin, isoniazid, pyrazinamide, and ethambutol daily for two months, followed by rifampin plus isoniazid twice weekly for four months. The HIV-positive patients who had no evidence of tuberculosis were then randomly assigned to receive either rifampin plus isoniazid or placebo twice weekly for a further six months. We also followed a comparison group of HIV-seronegative patients who received no further treatment for tuberculosis after six months.
  
  
  RESULTS
  After six months, 260 of 335 HIV-seropositive and 186 of 188 HIV-seronegative participants could be evaluated, and their rates of treatment failure were similar: 3.8 and 2.7 percent, respectively. At 24 months, the HIV-seropositive patients who received extended treatment had a relapse rate of 1.9 percent, as compared with 9 percent among the HIV-seropositive patients who received placebo for the second 6 months (P < 0.01). Extended treatment did not improve survival, however. Among the HIV-seronegative patients, 5.3 percent relapsed.
  
  
  CONCLUSIONS
  Among HIV-seropositive patients with pulmonary tuberculosis, extending treatment from 6 to 12 months reduces the rate of relapse but does not improve survival. The six-month program of partly intermittent antituberculous treatment may be an acceptable alternative when resources are limited.
authors.affiliation: Projet SIDA, Kinshasa, Zaire.
authors.forename: J H
authors.initials: JH
authors.lastname: Perriëns
authors.forename: M E
authors.initials: ME
authors.lastname: St Louis
authors.forename: Y B
authors.initials: YB
authors.lastname: Mukadi
authors.forename: C
authors.initials: C
authors.lastname: Brown
authors.forename: J
authors.initials: J
authors.lastname: Prignot
authors.forename: F
authors.initials: F
authors.lastname: Pouthier
authors.forename: F
authors.initials: F
authors.lastname: Portaels
authors.forename: J C
authors.initials: JC
authors.lastname: Willame
authors.forename: J K
authors.initials: JK
authors.lastname: Mandala
authors.forename: M
authors.initials: M
authors.lastname: Kaboto
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D005260:Female; D006679:HIV Seropositivity; D006801:Humans; D008297:Male; D011446:Prospective Studies; D016037:Single-Blind Method; D013997:Time Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy* / Q000401:mortality
chemical_list: D000904:Antibiotics, Antitubercular